Literature DB >> 8039305

Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

T Hoelting1, A Zielke, A E Siperstein, O H Clark, Q Y Duh.   

Abstract

The aggressiveness of follicular thyroid cancer (FTC) varies widely, and metastasis is the primary cause of death. Uncontrolled proliferation of cancer cells may be associated with loss of growth factor control. We investigated the effects of stimulating (epidermal growth factor [EGF]; thyreotropin [TSH] in low concentrations) and inhibiting growth factors (transforming growth factor beta 1 [TGF beta 1]; TSH in high concentrations) on invasion and growth of FTC cell lines from the thyroid tumor (FTC133) and from the lymph node (FTC236) and lung (FTC238) metastases of the same patient. Invasion-penetration through an 8 microns pore membrane, covered by Matrigel (basement membrane)-and growth were measured using the MTT-method. EGF (10 ng/ml) and TSH in low concentrations (1 mU/ml) stimulated invasion and growth of all FTC cell lines, but the amplitude of stimulation differed significantly. The parental cell line FTC133 was considerably more responsive to growth factor stimulation than the metastatic clones. Invasion of FTC133 was enhanced by 42% (EGF; p < 0.02) and 21% (TSH; p < 0.01), invasion of FTC236 by 8% (EGF; p < 0.02) and 8% (TSH; p < 0.01), and invasion of FTC238 by 9% (EGF; p < 0.02) and 8% (TSH; p < 0.01). Conversely, invasion and growth of FTC133 were significantly more inhibited by TGF beta 1 (10 ng/ml) and supraphysiologic concentrations of TSH (100 mU/ml) than the cell lines from the lymph node and lung metastases. At day 7, invasion of FTC133 was inhibited by 32% (TGF beta 1; p < 0.02) and 21% (TSH; p < 0.01), invasion of FTC236 by 18% (TGF beta 1; p < 0.02) and 11% (TSH; p < 0.01), and invasion of FTC238 by 16% (TGF beta 1; p < 0.02) and 12% (TSH; p < 0.01). Moreover, we analyzed growth factor independence in minimally supplemented or unsupplemented medium. Growth, but no invasion was evident when cells were cultured completely unsupplemented over 7 days. These results suggest that metastatic FTCs may have developed by escaping from the normal control of TSH and other growth factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039305     DOI: 10.1007/bf01753838

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  50 in total

Review 1.  Thyroid cell growth, differentiation and function in the FRTL-5 cell line: a survey.

Authors:  S P Bidey; A Lambert; W R Robertson
Journal:  J Endocrinol       Date:  1988-12       Impact factor: 4.286

2.  Distant metastases in differentiated thyroid carcinomas: a clinical and pathologic study.

Authors:  Y Mizukami; T Michigishi; A Nonomura; T Hashimoto; S Terahata; M Noguchi; K Hisada; F Matsubara
Journal:  Hum Pathol       Date:  1990-03       Impact factor: 3.466

Review 3.  Thyroid cancer: a lethal endocrine neoplasm.

Authors:  J Robbins; M J Merino; J D Boice; E Ron; K B Ain; H R Alexander; J A Norton; J Reynolds
Journal:  Ann Intern Med       Date:  1991-07-15       Impact factor: 25.391

4.  Control of human thyroid follicular cell proliferation in suspension and monolayer culture.

Authors:  D W Williams; D Wynford-Thomas; E D Williams
Journal:  Mol Cell Endocrinol       Date:  1987-05       Impact factor: 4.102

5.  Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

Authors:  M Lund-Johansen; R Bjerkvig; P A Humphrey; S H Bigner; D D Bigner; O D Laerum
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

6.  Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts.

Authors:  D E Chadwick; A E Lagarde
Journal:  J Natl Cancer Inst       Date:  1988-05-04       Impact factor: 13.506

7.  Growth regulation of normal thyroids and thyroid tumors in man.

Authors:  P E Goretzki; A Frilling; D Simon; H D Roeher
Journal:  Recent Results Cancer Res       Date:  1990

Review 8.  Thyroid cancer.

Authors:  O H Clark; Q Y Duh
Journal:  Med Clin North Am       Date:  1991-01       Impact factor: 5.456

9.  A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases.

Authors:  A Fusco; M Grieco; M Santoro; M T Berlingieri; S Pilotti; M A Pierotti; G Della Porta; G Vecchio
Journal:  Nature       Date:  1987 Jul 9-15       Impact factor: 49.962

10.  Thyrotropin binding and adenylate cyclase activation in normal and neoplastic human thyroid tissue: lack of effect of thyroglobulin.

Authors:  O H Clark; P L Gerend; R A Nissenson
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

View more
  7 in total

1.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

2.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

3.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

4.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

5.  [Growth and invasion of differentiated thyroid gland carcinoma: importance of signal transduction].

Authors:  T Hölting; O Y Duh; O H Clark; C Herfarth
Journal:  Langenbecks Arch Chir       Date:  1995

6.  Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer.

Authors:  Woo Kyung Lee; Won Gu Kim; Laura Fozzatti; Sunmi Park; Li Zhao; Mark C Willingham; David Lonard; Bert W O'Malley; Sheue-Yann Cheng
Journal:  Endocr Relat Cancer       Date:  2020-04       Impact factor: 5.678

7.  Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

Authors:  S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke
Journal:  Langenbecks Arch Surg       Date:  2006-10-12       Impact factor: 3.445

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.